BML Investment Partners Amends ARCA Biopharma Stake

TL;DR

**BML Investment Partners just updated their ARCA biopharma stake, watch for details.**

AI Summary

BML Investment Partners, L.P. has filed an amendment (SC 13G/A) indicating a change in their ownership of ARCA biopharma, Inc. common stock as of December 31, 2023. This filing, Amendment No. 2, updates their previous disclosures. While the specific percentage or number of shares is not detailed in the provided excerpt, the filing itself signals that BML Investment Partners, L.P. is a significant holder, and any change in their stake could influence investor perception and potentially the stock price of ARCA biopharma, Inc.

Why It Matters

Significant investors like BML Investment Partners, L.P. adjusting their holdings can signal their confidence (or lack thereof) in ARCA biopharma, Inc.'s future, potentially impacting the stock's valuation.

Risk Assessment

Risk Level: medium — Changes in significant investor holdings can introduce volatility, but without specific share counts, the immediate impact is unclear.

Analyst Insight

Investors should monitor subsequent filings from BML Investment Partners, L.P. or ARCA biopharma, Inc. for specific details on the change in ownership percentage or share count to fully assess the impact.

Key Players & Entities

• BML Investment Partners, L.P. (company) — the entity reporting its ownership in ARCA biopharma, Inc.
• ARCA biopharma, Inc. (company) — the subject company whose securities are being reported on
• December 31, 2023 (date) — the date of the event which required the filing of this statement
• Amendment No. 2 (number) — the specific amendment number for this filing

Forward-Looking Statements

• ARCA biopharma, Inc. stock may experience minor price fluctuations as investors react to the updated ownership information from BML Investment Partners, L.P. (ARCA biopharma, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti

Filing Documents

• arca13g020724.htm (SC 13G/A) — 57KB
• 0001616824-24-000034.txt ( ) — 59KB

(a)

Item 1(a). Name of Issuer: ARCA Biopharma, INC.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 10170 Church Ranch Way , Suite 100 , Westminster , CO

(a)

Item 2(a). Name of Person Filing: BML Investment Partners, L.P.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: 65 E Cedar - Suite 2 Zionsville, IN 46077

(c)

Item 2(c). Citizenship: Delaware

(d)

Item 2(d). Title of Class of Securities: Common Stock, $0.001 par value

(e)

Item 2(e). CUSIP Number: 00211Y506 Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n): (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ . Item 4. (a) Amount beneficially owned: 706,930 (b) Percent of class: 4.9 (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 706,930 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 706,930 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of s

View Full Filing

View this SC 13G/A filing on SEC EDGAR